The Lancet: Sinopharm vaccine is safe for boys ages 3 to 17 | Generated a strong immune response

A recent study from the research journalLancet’s infectious diseaseI threw that The Sinopharm vaccine is safe and elicited a “strong immune response after two doses” in children aged 3 to 17 years.

Although it remains to be seen how effective it is, which will be evaluated in phase three of the investigation, specialists reported in the journal that the so-called BBIBO-CorV is safe and well tolerated, “and that” it elicits strong humoral responses. (generation of antibodies) against SARS-CoV-2 infection after two doses’, based on phase one and two surveys in boys in this age group

The trial performed was randomized, double-blind and controlled. In both stages, we worked with healthy volunteers in age groups between 3 and 5 years, 6 and 12 years and 13 and 17 years, who received different doses of vaccination.

Regarding the doses, they were administered 28 days apart. 445 children participated in phase one, while 810 children were selected for phase two.

In lo that respecta a la seguridad, indicating that the reacción adversa más común fue dolor en el lugar de la inyección, seguida por fiebre, siendo that “en su mayoría la gravedad fue de leve a moderada” y fueron “transitorias o se resolvieron en A few days”.

Therefore, the scientists concluded at this point in the research that the inactivated covid 19 vaccine BBIBP-CorV, known commercially as Sinopharm, “is safe and well tolerated at all levels tested in participants aged three to 17. years”.

In addition, they added that the side effects mostly occurred after the first dose and were similar in frequency to those seen in participants aged 18 to 59 and those aged 60 and over.

The researchers of this study predicted that phase three for this age group will take place in the United Arab Emirates.s, where vaccines will be administered 21 days apart for additional data on safety, immunogenicity and efficacy.